

CURRICULUM VITAE

Eugene G. Levin, Ph.D.
Professor
Division of Vascular Biology
La Jolla Institute for Molecular Medicine
4570 Executive Dr. Suite 100
San Diego, CA 92121
Phone: 858-587-8788 x120
FAX: 858-587-4760

EDUCATION:

1973 - 1977 Ph.D., Biochemistry, University of California, Irvine, CA
1969 - 1971 M.S., Microbiology, Colorado State University, Fort Collins, CO
1965 - 1969 B.S., Microbiology, Pennsylvania State University, University Park, PA

RESEARCH AND PROFESSIONAL EXPERIENCE:

2005 - present Member, Torrey Pines Institute for Molecular Medicine
2000 - 2005 Professor, Vascular Biology Division, La Jolla Institute for Molecular Medicine
1990 - 2000 Associate Professor, Department of Molecular and Experimental Medicine, Department of Vascular Biology, The Scripps Research Institute, La Jolla, California
1984 - 1990 Assistant Member, Department of Molecular and Experimental Medicine, Scripps Clinic and Research Foundation, La Jolla, California
1979 - 1983 Research Associate, Department of Immunology, The Scripps Research Institute, La Jolla, California
1977 - 1979 Postdoctoral Research Fellow, Department of Immunology, The Scripps Research Institute, La Jolla, California

Patents:

10/408,415 and 03/10719 "Truncated 24kDa Fibroblast Growth Factor", Eugene G. Levin, Inventor.

FUNDING: (direct costs)

NIH (CA81209) 7/01/05-6/30/10 Inhibition of Migration by ATE+31	\$1,250,000
NIH (CA81209) 12/01/99 - 2/28/05 Negative Control of Migration by 24kD FGF-2	\$1,082,000

NIH (HL56775) 7/15/99 - 6/30/02 Endothelial Cell Diversity During Fetal Development	\$651,000
Pfeiffer Foundation Grant 11/01/98 - 11/01/01 Inhibition of Mammary Tumor Development by High Molecular Weight FGF	\$147,754
NIH (HL056775) 7/01/95-6/30/99 Regulation of Plasminogen Activator Expression	\$1,156,000
NIH (HL040435) 4/01/90-3/31/95 Tissue Plasminogen Activator from the Human Endothelium	\$985,000
NIH (HL030244) 1/01/84-12/31/90 Human Vascular Plasminogen Activators	\$1,080,000

PROFESSIONAL ACTIVITIES: (as of 1989)

1989	NIH Adjunct Study Section: University of Alabama
1990	NIH Adjunct Study Section: Cornell University Medical School
1992	NIH Adjunct Study Section: Harvard Medical School
1991-Pres.	American Heart Association, California Affiliate Peer Grant Review Committee
1996-1997	NIH Ad Hoc Reviewer/Pathology A Study Section
1996	Invited participant, NHLBI Workshop, Hemostatic Factors and The Nervous System, NIH
1997	Organizing Committee, VIth International Workshop on Molecular and Cellular Biology of Plasminogen Activation, San Diego
1996-1997	Austrian Science Foundation, Vienna, Austria, Peer Grant Review Committee
1998	NIH Adjunct Study Section: University of Michigan
1998-2002	American Heart Association, National Peer Grant Review Committee, Vascular Wall Biology
1999-2000	Vice Chairman - American Heart Association, California Affiliate, Peer Review Committee, Vascular Wall Biology
1999-2003	Scientific Research Committee, American Heart Association, California Affiliate

PUBLICATIONS (most recent of 62):

1. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK and Plow EF: Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. **Atherosclerosis and Thrombosis** 14:438-442, 1994.
2. Levin EG, del Zoppo GJ: Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. **Am J Pathol**, 144:855-861, 1994.
3. Levin EG: Gene expression and function of tissue plasminogen activator (tPA). In: *Fibrinolysis in Disease: Molecular Biology of the Chief Regulators of the*

- Fibrinolytic/Proteolytic Enzyme Systems*. Edited by P. Glas-Greenwalt, CRC Press, pp. 1-9, 1995.
4. Piotrowicz RS, Weber LA, Hickey E and Levin EG. Accelerated growth and senescence of arterial endothelial cells expressing the small molecular weight heat shock protein, HSP27. **FASEB J**, 9:1079-1084, 1995.
 5. Li S, Piotrowicz RS, Levin EG, Shyy YJ and Chien S. Fluid shear stress induces the phosphorylation of small heat shock proteins in vascular endothelial cells. **Am J Physiology: Cell Physiol**, 271:C994-C1000, 1996.
 6. Piotrowicz RS, Martin JL, Dillman WH, Levin EG. The 27-kDa heat shock protein facilitates basic fibroblast growth factor release from endothelial cells. **J Biol Chem**, 272:7042-7047, 1997.
 7. Levin EG, Santell L and Osborn KG. The expression of endothelial tissue plasminogen activator in vivo: A function defined by vessel size and anatomic location. **J Cell Sci**, 11:139-148, 1997.
 8. Piotrowicz RS and Levin EG. Baso-lateral membrane-associated heat shock protein 27 kDa and microfilament polymerization. **J Biol Chem.**, 272:25920-25927, 1997.
 9. Piotrowicz RS and Levin EG. Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration. **FASEB J**, 12:1481-1490, 1998.
 10. Santell L, Marotti KR and Levin EG. Targeting of tissue plasminogen activator into the regulated secretory pathway of neuroendocrine cells. **Brain Research**, 816(1):28-265, 1998.
 11. Piotrowicz RS, Maher PA and Levin EG. Dual Activities of 22-24 kDa Basic-Fibroblast Growth Factor: Inhibition of Migration and Stimulation of Proliferation. **J Cell Physiol**, 178(2):144-153, 1999.
 12. Levin EG, Banka CL and Parry GCN. Progressive and Transient Expression of Tissue Plasminogen Activator During Fetal Development. **Arterioscl Thromb Vasc Biol**, 20(6):1668-1674, 2000.
 13. Piotrowicz RS, L Ding, P Maher and EG Levin. Inhibition of cell migration by 24kD FGF-2 is dependent upon the estrogen receptor. **J Biol Chem**, 276:3963-70,2001.
 14. Ding, L., Donate F, Parry GCN, Maher PA, and Levin EG. Inhibition of cell migration and angiogenesis by the amino terminal end of 24kD basic fibroblast growth factor. **J Biol Chem.**, 277:31056-31061, 2002.
 15. Levin EG, Sikora L, Ding L, and Sriramarao P. Inhibition of tumor cell migration by a truncated form of 24kDa FGF-2 leads to suppression of tumor growth and angiogenesis in vivo. **Am J Pathol**, 164:1183-90, 2004.
 16. Pham NL, Franzen A, Levin EG. NF1 regulatory element functions as a repressor of tissue plasminogen activator expression. **Arterioscler Thromb Vasc Biol**, 24:982-7, 2004..
 17. Levin E. Cancer Therapy Through Control of Cell Migration. **Current Cancer Drug Target**, 7:505-18, 2005
 18. Eliceiri B, Pham N-L, Levin E.G. FAK mediates the inhibition of migration following ATE+31 treatment. **Biochemical Journal**, In revision, 2006